Search

Background: Esophageal cancer is a major public health issue, yet risk factors for its occurrence are still insufficiently known. This study aimed to estimate the global burden of esophageal cancer and its risk factors. Methods: This ecological study presented the incidence, mortality, and Disability-Adjusted Life Years (DALYs) of esophageal cancer in the world. This study collected the Global Burden of Disease study data from 1990 to 2019. Trends in esophageal cancer burden were assessed using the joinpoint regression analysis and calculating the average annual percent change (AAPC). Results: Globally, in 2019, in both sexes and all ages, the ASR for the incidence of esophageal cancer was 6.5 per 100,000 and for mortality, 6.1 per 100,000. The global proportion of DALYs for esophageal cancer attributable to selected behavioral, metabolic, and dietary risk factors was similar in males and females: chewing tobacco (3.8% vs. 5.1%), diet low in fruits (10.1% vs. 12.6%), diet low in vegetables (3.3% vs. 4.6%), and high body mass index (18.8% vs. 19.3%). However, the proportion of DALYs for esophageal cancer attributable to smoking and alcohol use was 4–5 times higher in males than in females (50.1% vs. 11.3%, and 29.6% vs. 5.1%, respectively). From 1990 to 2019, a significant decrease in global trends in rates of DALYs for esophageal cancer attributable to smoking (AAPC = −1.6%), chewing tobacco (AAPC = −0.5%), alcohol use (AAPC = −1.0%), a diet low in fruits (AAPC = −3.1%), and a diet low in vegetables (AAPC = −3.6%) was observed, while a significant increase in trends was observed in DALYs rates for esophageal cancer attributable to a high body mass index (AAPC = +0.4%). Conclusions: More epidemiological research is needed to elucidate the relationship between esophageal cancer and certain risk factors and guide prevention efforts. [ABSTRACT FROM AUTHOR]

Background and Objectives: Alzheimer's disease and other dementias represent some of the leading public health concerns worldwide. This study aimed to assess the global burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose in the last decades. Materials and Methods: A descriptive epidemiological study was conducted. The Global Burden of Disease (GBD) study data about deaths and Disability-Adjusted Life Years (DALYs) were used. All figures were presented as age-standardized rates (ASRs). The average annual percent change (AAPC) was computed using the Joinpoint regression analysis. Also, age-period-cohort analysis was performed. Results: A total of 2 million deaths from Alzheimer's disease and other dementias were reported worldwide in 2021, whereby the total number deaths from Alzheimer's disease and other dementias attributable to high fasting plasma glucose was 290,032 (98,900 males and 191,132 females) in 2021. The highest ASRs of burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose were found in Afghanistan, Iraq, Morocco, Qatar, and the United States of America, while the lowest ASRs were in Belarus and Mongolia. From 1990 to 2021, a significant increase (p < 0.001) was noted in ASRs of deaths and DALYs for Alzheimer's disease and other dementias attributable to high fasting plasma glucose. Looking at the GBD regions, the trends in ASRs for mortality and for DALYs of Alzheimer's disease and other dementias attributable to high fasting plasma glucose between 1990 and 2021 showed a growth 10-fold faster in High-income North America (AAPC = 2.0%, for both equally) and Central Asia (AAPC = 2.4% and AAPC = 2.5%, respectively) than in the region of High-income Asia Pacific (AAPC = 0.1% and AAPC = 0.2%, respectively). The relative risk of mortality and DALYs for Alzheimer's disease and other dementias attributable to high fasting plasma glucose demonstrated statistically significant (p < 0.0001) period and cohort effects, and net drift and local drifts. Conclusions: This study showed an increase in the global burden of Alzheimer's disease and other dementias attributable to high fasting plasma glucose in the last decades. Future successful entire-population strategies targeting high fasting plasma glucose may reduce the burden of a wide range of these diseases. [ABSTRACT FROM AUTHOR]